357 related articles for article (PubMed ID: 35228755)
21. Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.
Kobayashi Y; Arai H; Honda M
Curr Oncol; 2020 Aug; 27(4):225-228. PubMed ID: 32905370
[TBL] [Abstract][Full Text] [Related]
22. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma.
Ishihara H; Kondo T; Nakamura K; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Takagi T
Jpn J Clin Oncol; 2021 Dec; 51(12):1751-1756. PubMed ID: 34492101
[TBL] [Abstract][Full Text] [Related]
23. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
Wan X; Zhang Y; Tan C; Zeng X; Peng L
JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
[TBL] [Abstract][Full Text] [Related]
24. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients.
Thana M; Basappa NS; Ghosh S; Kollmannsberger CK; Heng DYC; Hansen AR; Graham J; Soulières D; Reaume MN; Lalani AA; Castonguay V; Bjarnason GA; Patenaude F; Breau RH; Pouliot F; Kapoor A; Wood LA
Clin Genitourin Cancer; 2022 Jun; 20(3):210-218. PubMed ID: 35115252
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C; ;
BJU Int; 2024 Feb; 133 Suppl 3():57-67. PubMed ID: 37986556
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
[TBL] [Abstract][Full Text] [Related]
29. European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma.
Ali S; Camarero J; Hennik P; Bolstad B; Sommerfelt Grønvold M; Syvertsen C; Oddvar Strøm B; Ökvist M; Josephson F; Keller-Stanislawski B; Zafiropoulos N; Pean E; Bergh J; da Rocha Dias S; Pignatti F
ESMO Open; 2020 Nov; 5(6):e000798. PubMed ID: 33188050
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
[TBL] [Abstract][Full Text] [Related]
31. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
32. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
George G; Schmidt L; Tolat P; Riese M; Kilari D
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
[TBL] [Abstract][Full Text] [Related]
33. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Buckley HL; Collinson FJ; Ainsworth G; Poad H; Flanagan L; Katona E; Howard HC; Murden G; Banks RE; Brown J; Velikova G; Waddell T; Fife K; Nathan PD; Larkin J; Powles T; Brown SR; Vasudev NS
BMC Cancer; 2019 Nov; 19(1):1102. PubMed ID: 31727024
[TBL] [Abstract][Full Text] [Related]
34. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
Yamashita S; Hamamoto S; Furukawa J; Fujita K; Takahashi M; Miyake M; Ito N; Iwamoto H; Kohjimoto Y; Hara I
Sci Rep; 2024 May; 14(1):12398. PubMed ID: 38811687
[TBL] [Abstract][Full Text] [Related]
36. [Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].
Rexer H; Steiner T; Bergmann L
Urologe A; 2017 Jun; 56(6):802-803. PubMed ID: 28536740
[No Abstract] [Full Text] [Related]
37. Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.
Gupta R; Ornstein MC; Li H; Allman KD; Wood LS; Gilligan T; Garcia JA; Merveldt DV; Hammers HJ; Rini BI
Clin Genitourin Cancer; 2020 Dec; 18(6):429-435. PubMed ID: 32800717
[TBL] [Abstract][Full Text] [Related]
38. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Ueda K; Suekane S; Kurose H; Ito N; Ogasawara N; Hiroshige T; Chikui K; Ejima K; Uemura K; Nakiri M; Nishihara K; Igawa T
Jpn J Clin Oncol; 2022 May; 52(5):479-485. PubMed ID: 35141749
[TBL] [Abstract][Full Text] [Related]
39. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
40. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
